Content about Chemistry

November 4, 2013

The Food and Drug Administration has asked Ariad Pharmaceuticals to suspend marketing and sales of a chemotherapy drug for leukemia due to the risk of life-threatening side effects, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has asked Ariad Pharmaceuticals to suspend marketing and sales of a chemotherapy drug for leukemia due to the risk of life-threatening side effects, the agency said.

November 4, 2013

Procter & Gamble on Monday announced that celebrity chef and nutritionist Chef LaLa, and medical expert Jorge Rodriguez, will share health and nutrition tips to help families reduce the chances of heartburn as part of a brand initiative supporting Prilosec OTC.

CINCINNATI — Procter & Gamble on Monday announced that celebrity chef and nutritionist Chef LaLa, and medical expert Jorge Rodriguez, will share health and nutrition tips to help families reduce the chances of heartburn as part of a brand initiative supporting Prilosec OTC. The bilingual education about how to help minimize frequent heartburn addresses a common health issue in U.S. Hispanic households, the company noted. 

November 1, 2013

Mylan expects to be the first to market with a generic version of a drug for treating patients with gout, the company said Friday, though its filing has triggered a lawsuit from the makers of the branded version.

PITTSBURGH — Mylan expects to be the first to market with a generic version of a drug for treating patients with gout, the company said Friday, though its filing has triggered a lawsuit from the makers of the branded version.

October 31, 2013

Impax Labs and Tolmar announced that the Food and Drug Administration has given final approval to Tolmar's generic version of Solaraze gel.

HAYWARD, Calif., and FORT COLLINS, Colo.  — Impax Labs and Tolmar announced that the Food and Drug Administration has given final approval to Tolmar's generic version of Solaraze (diclofenac sodium) gel in the 3% strength.

October 30, 2013

A division of Kroger Co. has placed an initial order for Alkaline88, a bottled water brand produced using a proprietary electrolysis beverage process.

SCOTTSDALE, Ariz. — A division of Kroger Co. has placed an initial order for Alkaline88, a bottled water brand produced using a proprietary electrolysis beverage process.

The Alkaline Water Co. announced the order Wednesday, from Smiths Food and Drug Stores, which operates 131 stores in Utah, Nevada, New Mexico, Arizona, Montana, Idaho and Wyoming. Alkaline sells the water in 3-L and 1-gal. sizes.

October 30, 2013

A trade group for supplement makers is suggesting that people with diabetes talk to their physicians about chromium picolinate supplementation, based on a recent study.

WASHINGTON — A trade group for supplement makers is suggesting that people with diabetes talk to their physicians about chromium picolinate supplementation, based on a recent study.

October 30, 2013

STUF Men’s Defense, a skin care line just for guys, has announced that it is now being sold on Amazon.com.

BOCA RATON, Fla. — STUF Men’s Defense, a skin care line just for guys, has announced that it is now being sold on Amazon.com.

Commissioned by 11-time Olympic medalist Mark Spitz, STUF Men’s Defense is made from naturally produced ingredients, including combinations of herbs, antioxidants and vitamins, and the products do not contain any animal byproducts, mineral oils, parabens, colorants or phthalates.

October 29, 2013

Actavis had sales of $2.01 billion in third quarter 2013, a 57% increase over the same period last year, the drug maker said Tuesday.

DUBLIN — Actavis had sales of $2.01 billion in third quarter 2013, a 57% increase over the same period last year, the drug maker said Tuesday.

Profits for the quarter were $65.5 million, down from $76.7 million in third quarter 2012. The quarter's results exclude figures from Ireland-based Warner Chilcott, which Actavis acquired at the beginning of the month.

October 29, 2013

Generic drug maker Amneal Pharmaceuticals is seeking Food and Drug Administration approval for a gout drug, prompting a lawsuit from the maker of the branded version, according to published reports.

NEW YORK — Generic drug maker Amneal Pharmaceuticals is seeking Food and Drug Administration approval for a gout drug, prompting a lawsuit from the maker of the branded version, according to published reports.

Law360 reported that Takeda Pharmaceuticals USA had sued Amneal in the U.S. District Court for the District of Delaware over the drug Colcrys (colchicine), used to treat gout and familial Mediterranean fever.

October 25, 2013

The Food and Drug Administration has approved a new opioid painkiller made by Zogenix, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new opioid painkiller made by Zogenix, the agency said Friday.

The FDA announced the approval of Zohydro ER (hydrocodone) extended-release capsules for the management of pain severe enough to require daily, around-the-clock, long-term treatment. The agency said the drug was the first extended-release hydrocodone product not combined with another drug, such as acetaminophen, to be approved by the agency.

October 25, 2013

The Food and Drug Administration plans to recommend stronger regulations for a commonly used opioid painkiller.

SILVER SPRING, Md. — The Food and Drug Administration plans to recommend stronger regulations for a commonly used opioid painkiller.

October 25, 2013

The Food and Drug Administration plans to officially recommend that products containing 15 mg or less of the opioid painkiller hydrocodone be rescheduled as Schedule II controlled substances, from the current Schedule III classification. While the idea is to combat abuse and misuse of the drugs, pharmacy groups say the rescheduling would make them harder to obtain for patients who legitimately need them.

The desire to combat abuse and misuse of prescription drugs — now a worse problem in the United States than cocaine or heroin — is laudable, but unlike those two drugs, hydrocodone has a legitimate use as a painkiller, and it's the people who are using it properly and legally who will end up losing.

The Food and Drug Administration plans to officially recommend that products containing 15 mg or less of the opioid painkiller hydrocodone be rescheduled as Schedule II controlled substances, from the current Schedule III classification. While the idea is to combat abuse and misuse of the drugs, pharmacy groups say the rescheduling would make them harder to obtain for patients who legitimately need them.

October 23, 2013

The Food and Drug Administration plans to complete its phase out of inhalers that contain ozone-depleting chlorofluorocarbons by the end of the year, the agency said Wednesday.

SILVER SPRING, Md. — The Food and Drug Administration plans to complete its phase out of inhalers that contain ozone-depleting chlorofluorocarbons by the end of the year, the agency said Wednesday.

October 23, 2013

Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

NEWARK, Calif. — Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

The drug maker announced that it had sold its interest in the Type 2 diabetes therapeutic area to PDL for $240.5 million, which it plans to use to acquire rights to products it said would drive long-term growth and build on its expertise in pain and neurology.

October 23, 2013

Drug maker Hospira is investing more than $200,000 at a plant in Rocky Mount, N.C., that will evaluate and test more than 450 products, the company said Wednesday.

ROCKY MOUNT, N.C. — Drug maker Hospira is investing more than $200,000 at a plant in Rocky Mount, N.C., that will evaluate and test more than 450 products, the company said Wednesday.

Hospira had a ribbon-cutting ceremony to announce the opening of its new quality and analytics testing laboratory, attended by North Carolina Gov. Pat McCrory and other political leaders from the state.

October 23, 2013

Out of Africa, which is a line of natural and vegan skin care products using 100% pure, unrefined shea butter, is sponsoring in November the Shine On Sierra Leone’s Cash & Rocket VolunTourism Trip Sierra Leone, which will launch the building of the first and only secondary school in the Bongema Village.

MARINA DEL REY, Calif. — Out of Africa, which is a line of natural and vegan skin care products using 100% pure, unrefined shea butter, is sponsoring in November the Shine On Sierra Leone’s Cash & Rocket VolunTourism Trip Sierra Leone, which will launch the building of the first and only secondary school in the Bongema Village.

October 22, 2013

The Food and Drug Administration has approved drugs for depression and smoking cessation made by Jubilant Life Sciences, the company said.

NOIDA, India — The Food and Drug Administration has approved drugs for depression and smoking cessation made by Jubilant Life Sciences, the company said.

Jubilant, based in India, announced the approval of generic bupropion hydrochloride extended-release tablets in the 100-mg, 150-mg and 200-mg strengths, and another bupropion hydrochloride extended-release tablet product in the 150-mg strength.

The first product is a generic version of GlaxoSmithKline's antidepressant Wellbutrin SR, while the second is a version of GSK's anti-smoking drug Zyban.

October 21, 2013

The Food and Drug Administration has approved a pain drug made by Iroko Pharmaceuticals, Iroko said.

PHILADELPHIA — The Food and Drug Administration has approved a pain drug made by Iroko Pharmaceuticals, Iroko said.

The drug maker announced the approval of Zorvolex (diclofenac) capsules for mild to moderate acute pain in adults. The drug is a non-steroidal anti-inflammatory drug, or NSAID, belonging to the same class as the common analgesic drug ibuprofen. Zorvolex was approved at dosage strengths 20% lower than currently available diclofenac products, the company said.

October 21, 2013

The Food and Drug Administration has approved a new drug made by Actelion Pharmaceuticals for treating pulmonary arterial hypertension.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Actelion Pharmaceuticals for treating pulmonary arterial hypertension.

The agency announced the approval of Opsumit (macitentan) for adults with PAH, a chronic, progressive and debilitating disease caused by high blood pressure in the arteries that connect the heart to the lungs that can lead to death or the need for lung transplantation.

October 17, 2013

UrgentRx — developer of fast-acting, over-the-counter, flavored powder medications — on Thursday announced the addition of CVS, OfficeMax and Paradies Stores to the company's list of retail partners.

DENVER — UrgentRx — developer of fast-acting, over-the-counter, flavored powder medications — on Thursday announced the addition of CVS, OfficeMax and Paradies Stores to the company's list of retail partners. 

October 16, 2013

The Vitamin Shoppe on Wednesday announced the grand opening of its new distribution center in Ashland, Va.

NORTH BERGEN, N.J. — The Vitamin Shoppe on Wednesday announced the grand opening of its new distribution center in Ashland, Va. The new 311,740 square-foot facility began receiving inbound inventory in June 2013 and outbound shipments to stores began in September. 

October 15, 2013

Actavis is hoping to become the first to market a generic version of a drug used to treat patients who have become dependent on opioid drugs, triggering a lawsuit from the branded drug's manufacturer.

DUBLIN — Actavis is hoping to become the first to market a generic version of a drug used to treat patients who have become dependent on opioid drugs, triggering a lawsuit from the branded drug's manufacturer.

The generic drug maker said it had filed a regulatory approval application with the Food and Drug Administration for buprenorphine hydrochloride and naloxone hydrochloride sublingual film in the 2-mg/0.5-mg and 8-mg/2-mg strengths. The drug is a generic version of Reckitt Benckiser's Suboxone.

October 14, 2013

Allergy sufferers will have a new treatment option available to them by the spring allergy season. Sanofi on Friday announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older.

PARIS — Allergy sufferers will have a new treatment option available to them by the spring allergy season. Sanofi on Friday announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older. 

Nasacort is the first and only nasal corticosteroid to be available without a prescription and will be marketed by Sanofi's consumer healthcare division, Chattem.

October 11, 2013

The global market for drugs to treat constipation resulting from use of opioid painkillers will increase more than tenfold by 2017, according to new research.

LONDON — The global market for drugs to treat constipation resulting from use of opioid painkillers will increase more than tenfold by 2017, according to new research.

October 10, 2013

A subsidiary of Johnson & Johnson has acquired rights to an experimental drug for hepatitis C from GlaxoSmithKline.

TITUSVILLE, N.J. — A subsidiary of Johnson & Johnson has acquired rights to an experimental drug for hepatitis C from GlaxoSmithKline.

Janssen Pharmaceuticals announced that it had bought, for an undisclosed among, the drug GSK2336805 from GSK. The drug, which belongs to a class known as NS5a replication complex inhibitors, is currently in mid-stage development.